-
EP3236948
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3236948
| EP3236948 - COMBINATION OF RAF INHIBITORS AND AURORA KINASE INHIBITORS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 27.11.2020 Database last updated on 03.09.2024 | |
| Former | Grant of patent is intended Status updated on 01.03.2020 | ||
| Former | Request for examination was made Status updated on 29.09.2017 | ||
| Former | The international publication has been made Status updated on 19.07.2017 | Most recent event Tooltip | 27.11.2020 | Application deemed to be withdrawn | published on 30.12.2020 [2020/53] | Applicant(s) | For all designated states DOT Therapeutics-1, Inc. 2765 Sand Hill Road Menlo Park, CA 94025 / US | [2020/18] |
| Former [2017/44] | For all designated states Millennium Pharmaceuticals, Inc. 40 Landsdowne Street Cambridge, MA 02139 / US | Inventor(s) | 01 /
BOZON, Viviana 99 Pickwick Road West Newton, MA 02465 / US | 02 /
GALVIN, Katherine, M. 52 Greenlawn Avenue Newton, MA 02459 / US | [2017/44] | Representative(s) | Harris, Jennifer Lucy Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB | [2017/44] | Application number, filing date | 15874329.4 | 22.12.2015 | [2017/44] | WO2015US67459 | Priority number, date | US201462096020P | 23.12.2014 Original published format: US 201462096020 P | [2017/44] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2016106357 | Date: | 30.06.2016 | Language: | EN | [2016/26] | Type: | A1 Application with search report | No.: | EP3236948 | Date: | 01.11.2017 | Language: | EN | The application published by WIPO in one of the EPO official languages on 30.06.2016 takes the place of the publication of the European patent application. | [2017/44] | Search report(s) | International search report - published on: | US | 30.06.2016 | (Supplementary) European search report - dispatched on: | EP | 31.08.2018 | Classification | IPC: | A61K31/506, A61K31/55, A61K45/06, A61P35/00, A61K9/14 | [2018/39] | CPC: |
A61K31/506 (EP,US);
A61K31/55 (EP,US);
A61K45/06 (EP,US);
A61P35/00 (EP,US);
A61K2300/00 (US)
| C-Set: |
A61K31/506, A61K2300/00 (US,EP);
A61K31/55, A61K2300/00 (EP,US) |
| Former IPC [2017/44] | A61K9/14 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/44] | Title | German: | KOMBINATION AUS RAF-INHIBITOREN UND AURORAKINASE-INHIBITOREN | [2017/44] | English: | COMBINATION OF RAF INHIBITORS AND AURORA KINASE INHIBITORS | [2017/44] | French: | COMBINAISON D'INHIBITEURS DE RAF ET D'INHIBITEURS DE KINASES AURORA | [2017/44] | Entry into regional phase | 19.07.2017 | National basic fee paid | 19.07.2017 | Search fee paid | 19.07.2017 | Designation fee(s) paid | 19.07.2017 | Examination fee paid | Examination procedure | 19.07.2017 | Examination requested [2017/44] | 19.07.2017 | Date on which the examining division has become responsible | 26.03.2019 | Amendment by applicant (claims and/or description) | 02.03.2020 | Communication of intention to grant the patent | 14.07.2020 | Application deemed to be withdrawn, date of legal effect [2020/53] | 14.08.2020 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2020/53] | Fees paid | Renewal fee | 27.12.2017 | Renewal fee patent year 03 | 31.12.2018 | Renewal fee patent year 04 | 27.12.2019 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2013144923 (TAKEDA PHARMACEUTICAL [JP]) [A] 1-15 * abstract * * page 4, paragraph 19; claim - *; | [Y]US2013303519 (ECSEDY JEFFREY A [US], et al) [Y] 1-7,9-12 * abstract *; | [E]WO2015193212 (WORLDWIDE INNOVATIVE NETWORK [FR]) [E] 1-8 * page 5, line 21 - line 23 * * page 6, line 8 - line 9 * * tables 1,6,7 * * claim 15 *; | [Y] - MIDDLETON M ET AL, "First-in-human phase 1 study of MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors, including BRAF/NRAS-mutant melanoma", EUROPEAN JOURNAL OF CANCER, & 26TH EORTC-NCI-AACR SYMPOSIUM ON MOLECULAR TARGETS AND CANCER THERAPEUTICS; BARCELONA, SPAIN; NOVEMBER 18 -21, 2014, (201411), vol. 50, no. Suppl. 6, ISSN 0959-8049, page 117, XP002784040 [Y] 1-7,9-12 * the whole document * DOI: http://dx.doi.org/10.1016/S0959-8049(14)70490-3 | [XP] - "A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies", (20141230), ClinicalTrials.gov, URL: https://clinicaltrials.gov/ct2/show/NCT02327169, (20180820), XP002784013 [XP] 1-15 * the whole document * | International search | [Y]US2006128624 (CHEUNG WING [US], et al) [Y] 38* entire document *; | [Y]US2009036419 (CHEN WEIRONG [US], et al) [Y] 29-31, 38 * entire document *; | [Y]US2013245039 (HIGGINS BRIAN [US], et al) [Y] 31 * entire document *; | [Y]US2013303519 (ECSEDY JEFFREY A [US], et al) [Y] 29-31, 38 * entire document *; | [Y]WO2014018725 (NOVARTIS AG [CH], et al) [Y] 30, 38 * entire document *; | [X]US2014194442 (SOLCA FLAVIO [AT], et al) [X] 1-7, 20 * entire document * |